Robotic surgery limits blood loss in patients with bladder cancer | CDC: New HIV cases involving MSM rising | Study yields promising results for skin infection drug
Web Version
 
 
December 21, 2012
AABB SmartBrief
News for the transfusion medicine and cellular therapy community
SIGN UP|FORWARD|ARCHIVE

Top StorySponsored By
Robotic surgery limits blood loss in patients with bladder cancer
Compared with open radical cystectomy, robotic-assisted laparoscopy for invasive bladder cancer led to 50% less blood loss, reduced hospital stays and a 20% lower transfusion rate, according to a randomized study published in the Journal of Urology. The study found no significant difference in cancer outcomes. "Our study validates the concept of randomizing patients with bladder cancer undergoing radical cystectomy to an open or robotic approach," the researchers said. MedPage Today (free registration) (12/20)
Share: LinkedInTwitterFacebookGoogle+Email
 
Hemo bioscience has received FDA clearance for its complement coated control cells. Hemo bioscience C3 Control Cells can be used as a control to confirm the efficacy of the AHG reagent used during Direct and Indirect Anti-Globulin tests. For details regarding pricing, manufacturing schedule, and distribution channels email us or call 866-332-2835.
Advertisement
 
Science & Health
CDC: New HIV cases involving MSM rising
The number of new HIV infections among young men who have sex with men rose by 22% from 2008 to 2010, and MSM now account for 66% of all new infections, according to a CDC report. The rate of new HIV cases among black women dropped 21%, but the total number of new HIV infections held steady at around 47,500. Reuters (12/19)
Share: LinkedInTwitterFacebookGoogle+Email
Study yields promising results for skin infection drug
The antibiotic oritavancin performed comparably with standard-of-care vancomycin in terms of efficacy, according to findings from a late-stage trial. The drug met the primary endpoint of the study, which was to halt the spread of the infection and to eliminate fever. The drug was tested for the treatment of acute bacterial skin and skin structure infections by gram-positive bacteria, including methicillin-resistant Staphylococcus aureus. Reuters (12/20)
Share: LinkedInTwitterFacebookGoogle+Email
Emerging Trends
Mobile app gives patients quick access to hospital safety scores
Leapfrog Group has introduced a Hospital Safety Score app, which includes patient-safety letter grades for more than 2,600 hospitals. The scores are based on measures such as infections, preventable errors and accidents. The app features GPS-supported search to connect users to nearby facilities, a map display, full grade details and a guide for hospital patients. Health Data Management (12/19)
Share: LinkedInTwitterFacebookGoogle+Email
Industry News & Practice
Report: Most states unprepared for health emergencies
Only five states met eight of the 10 key measures for public emergency preparedness, according to an annual report released by the Trust for America's Health and the Robert Wood Johnson Foundation. Researchers found that 35 states, along with Washington, D.C., got a score of six or lower, with Kansas and Montana each receiving the lowest score of three. HealthDay News (12/19)
Share: LinkedInTwitterFacebookGoogle+Email
GSK, GlycoVaxyn collaborate on bacterial vaccine development
GlaxoSmithKline Biologicals and GlycoVaxyn agreed to use the latter's bioconjugation technology to develop novel bacterial vaccines. The deal, which covers a set of pathogen targets, gives GSK an exclusive licensing option. GSK will give GlycoVaxyn an upfront payment and equity investment plus milestone fees and royalties. Genetic Engineering & Biotechnology News (12/19)
Share: LinkedInTwitterFacebookGoogle+Email
Cevec licenses cell line technologies to S. Korean drugmaker
Yuhan secured the rights to use Cevec Pharmaceuticals' CAP-T and CAP cell expression systems to develop and manufacture various therapeutic proteins. CAP-T CAP cells are nontumor origin cell lines that demonstrate high protein expression and humanlike post-translational modifications. Genetic Engineering & Biotechnology News (12/20)
Share: LinkedInTwitterFacebookGoogle+Email
Government & Regulatory
European regulators approve iron overload drug
The European Commission has granted Novartis approval for deferasirox to reduce iron overload in patients with nontransfusion-dependent thalassemia syndrome receiving chelation treatment. The approval was based on a study that showed use of deferasirox can lead to significant dose-dependent reduction in iron levels in the body. RTT News (12/21)
Share: LinkedInTwitterFacebookGoogle+Email
FDA extends registration renewal deadline for medtech companies
The deadline for medical device establishments to renew their registration with the FDA for the fiscal year ending Sept. 30, 2013, has been pushed back from Dec. 31 to Jan. 31. The one-month extension is intended to enable manufacturers to satisfy new FDA standards on medical device listing and registration. MassDevice.com (Boston) (12/18)
Share: LinkedInTwitterFacebookGoogle+Email
Online database makes MU measures, objectives available
Data on meaningful use clinical quality measures, menu objectives and other corresponding details are now available at the U.S. Health Information Knowledgebase. The online database features search, comparison, analysis and download capabilities for 2011-13 and 2014 quality measures, as well as stages 1 and 2 meaningful use information. BeckersHospitalReview.com (12/19)
Share: LinkedInTwitterFacebookGoogle+Email
Association News
Transfusion News video explores progress in treatment for thrombotic thrombocytopenic purpura
A video posted on the Transfusion News website describes the use of immunomodulation therapy to help manage thrombotic thrombocytopenic purpura, or TTP, which is a rare but serious blood disorder that can cause catastrophic damage if not quickly diagnosed and treated. The video points out that earlier administration of rituximab, often with corticosteroids, may result in better patient outcomes. Progress in the treatment of TTP is discussed in an editorial and two reports appearing in the December issue of "Transfusion." Transfusion News is produced through a partnership between Ortho Clinical Diagnostics and AABB. The site features videos, articles, breaking news and commentary from transfusion and cellular therapy experts. Transfusion News may be accessed through the website for the journal "Transfusion," under "Special Features," or directly at www.TransfusionNews.com.
Share: LinkedInTwitterFacebookGoogle+Email
Who's Hiring?
Position TitleCompany NameLocation
Laboratory ManagerCreative Testing SolutionsUS - IL - Chicago
DIRECTOR, REGIONAL CENTER OPERATIONS IIUnited BloodUS - NV - Las Vegas
Quality SpecialistBlood Systems, Inc.US - NV - Las Vegas
Laboratory SupervisorCreative Testing SolutionsUS - IL - Chicago
LABORATORY MANAGERUnited Blood ServicesUS - NV - Las Vegas
DIRECTOR, COMMUNITY CENTER IUnited Blood ServicesUS - NV - Reno
QA SpecialistSan Diego Blood BankUS - CA
West Coast Account ManagerMacopharma USAUS - Nationwide
Reference TechnologistLifeStreamUS - CA - San Bernardino
Director, Patient Blood ManagementAABBUS - MD - Bethesda
Click here to view more job listings.
 
SmartQuote
How we spend our days is, of course, how we spend our lives."
-- Annie Dillard,
American author
Share: LinkedInTwitterFacebookGoogle+Email
Learn more about AABB® ->Homepage | Join AABB | Conferences | Marketplace | AABB CareerLink
Subscriber Tools
Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
 
Editor:  Tom Parks
Managing Editor:  Amanda Horn
Advertising Manager:  Annette Bacchus
  M: 240.333.6604
 
 

Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2014 SmartBrief, Inc.®
Privacy policy |  Legal Information